Matthew T Neal1, Michael D Chan2, John T Lucas2, Amritraj Loganathan3, Christine Dillingham3, Edward Pan4, John H Stewart5, J Daniel Bourland2, Edward G Shaw2, Stephen B Tatter3, Thomas L Ellis3. 1. Department of Neurosurgery, Wake Forest University, Winston-Salem, North Carolina, USA. Electronic address: mneal@wakehealth.edu. 2. Department of Radiation Oncology, Wake Forest University, Winston-Salem, North Carolina, USA. 3. Department of Neurosurgery, Wake Forest University, Winston-Salem, North Carolina, USA. 4. Department of Neurology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 5. Tumor Immunotherapy Program, Wake Forest University, Winston-Salem, North Carolina, USA.
Abstract
OBJECTIVE: This study sought to assess clinical outcomes in patients receiving gamma knife radiosurgery (GK) for treatment of brain metastases from melanoma and evaluate for potential predictive factors. METHODS: We reviewed 188 GK procedures in 129 consecutive patients that were treated for brain metastases from melanoma. The population consisted of 84 males and 45 females with a median age of 57 years. Fifty-five patients (43%) had a single metastasis. Seventy-one patients (55%) received chemotherapy, 58 patients (45%) received biologic agents, and 36 patients (28%) received prior whole brain radiation therapy (WBRT). The median marginal dose was 18.8 Gy (range 12 to 24 Gy). RESULTS: Actuarial survival was 52%, 26%, and 13% at 6, 12, and 24 months, respectively. The median survival time was 6.7 months. Local tumor control was 95%, 81% 53% at 6, 12, and 24 months, respectively. The median time to LBF was 25.2 months. Freedom from distant brain failure was 40%, 29%, and 10% at 6, 12, and 24 months, and the median time to DBF was 4.6 months. At the time of data analysis, 108 patients (84%) had died. Fifty-eight patients (52%) died from neurologic death. The median time to neurologic death from GK treatment was 7.9 months. Multivariate analysis revealed that hemorrhage of metastases prior to GK (P = .02) and LBF (P = .03) were the dominant predictors of neurologic death. CONCLUSIONS: GK achieves excellent local control and may improve outcomes as a component of a multidisciplinary treatment strategy. Distant brain failure and neurologic demise remain problematic and prospective trials are necessary.
OBJECTIVE: This study sought to assess clinical outcomes in patients receiving gamma knife radiosurgery (GK) for treatment of brain metastases from melanoma and evaluate for potential predictive factors. METHODS: We reviewed 188 GK procedures in 129 consecutive patients that were treated for brain metastases from melanoma. The population consisted of 84 males and 45 females with a median age of 57 years. Fifty-five patients (43%) had a single metastasis. Seventy-one patients (55%) received chemotherapy, 58 patients (45%) received biologic agents, and 36 patients (28%) received prior whole brain radiation therapy (WBRT). The median marginal dose was 18.8 Gy (range 12 to 24 Gy). RESULTS: Actuarial survival was 52%, 26%, and 13% at 6, 12, and 24 months, respectively. The median survival time was 6.7 months. Local tumor control was 95%, 81% 53% at 6, 12, and 24 months, respectively. The median time to LBF was 25.2 months. Freedom from distant brain failure was 40%, 29%, and 10% at 6, 12, and 24 months, and the median time to DBF was 4.6 months. At the time of data analysis, 108 patients (84%) had died. Fifty-eight patients (52%) died from neurologic death. The median time to neurologic death from GK treatment was 7.9 months. Multivariate analysis revealed that hemorrhage of metastases prior to GK (P = .02) and LBF (P = .03) were the dominant predictors of neurologic death. CONCLUSIONS: GK achieves excellent local control and may improve outcomes as a component of a multidisciplinary treatment strategy. Distant brain failure and neurologic demise remain problematic and prospective trials are necessary.
Authors: Paul J Black; Brandi R Page; John T Lucas; Ryan T Hughes; Adrian W Laxton; Stephen B Tatter; Michael T Munley; Michael D Chan Journal: J Radiosurg SBRT Date: 2015
Authors: Michael C LeCompte; Emory McTyre; Adrianna Henson; Michael Farris; Catherine Okoukoni; Christina K Cramer; Pierre Triozzi; Jimmy Ruiz; Kounosuke Watabe; Hui-Wen Lo; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Xiaobo Zhou; Michael Chan Journal: Cureus Date: 2017-12-11
Authors: Lauren E Haydu; Serigne N Lo; Jennifer L McQuade; Rodabe N Amaria; Jennifer Wargo; Merrick I Ross; Janice N Cormier; Anthony Lucci; Jeffrey E Lee; Sherise D Ferguson; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Jonathan R Stretch; Patrick Hwu; Sapna P Patel; Adi Diab; Michael K K Wong; Isabella C Glitza Oliva; Hussein Tawbi; Matteo S Carlino; Alexander M Menzies; Georgina V Long; Alexander J Lazar; Michael T Tetzlaff; Richard A Scolyer; Jeffrey E Gershenwald; John F Thompson; Michael A Davies Journal: J Clin Oncol Date: 2020-01-28 Impact factor: 44.544
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss Journal: Rep Pract Oncol Radiother Date: 2015-12-29
Authors: John T Lucas; Hentry G Colmer; Lance White; Nora Fitzgerald; Scott Isom; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Michael C LeCompte; Ryan T Hughes; Michael Farris; Adrianna Masters; Michael H Soike; Claire Lanier; Chase Glenn; Christina K Cramer; Kounosuke Watabe; Jing Su; Jimmy Ruiz; Christopher T Whitlow; Ge Wang; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130